Mechthild Krause, Prof.

A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C) Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported…

Validation of a DNA methylation classifier hypoxia-M as prognosticator for patients with postoperative radiochemotherapy in head and neck cancer. @dkfz.bsky.social #radonc

www.sciencedirect.com/science/arti...

Application of a preclinical 18-gene classifier to patients with locally advanced HNSCC In a previous preclinical trial on human HNSCC xenografts, 18 genes were predictive for adding cetuximab to fractionated radiotherapy. Here, we apply …

Another dataset on the potential of xenografts as valuable models for the development of biomarkers for individualized radiotherapy - along with the robustness of biomarkers predicting local control in xenografts (IR+Cetux) and in patients (radiochemo).
www.sciencedirect.com/science/arti...

Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma Paediatric high-grade gliomas (pedHGGs) have a dismal prognosis, often characterised by early and diffuse disease progression. Novel treatment approac…

In pediatric diffuse midline glioma/diffuse intrinsic pontine glioma, craniospinal spread is a frequent cause of death. Here, safety of combining craniospinal irradiation with temozolomide is shown, informing future clinical trial design (e.g., SIOPE HGG-01).
www.sciencedirect.com/science/arti...

Model validation confirms variable relative biological effectiveness and elevated periventricular sensitivity after proton therapy of brain tumors This study validates recently proposed voxel-wise and patient-wise predictive models for localization and occurrence of late radiation-induced contras…

Independent validation of NTCP models for predicting radiation induced contrast enhancements after proton therapy - increased periventricular radiosensitivity. Variable RBE clinically relevant, consideration will further improve safety of proton radiotherapy.
www.sciencedirect.com/science/arti...

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However…

Read the paper on radiotherapy with immun checkpoint and TK inhibitors - ESTRO/ESMO consensus about risks of combination
www.sciencedirect.com/science/arti...

#WissenschaftlicheIntegritaet: Die Leitlinie 14 des Kodex beschäftigt sich mit der #Autorschaft: Wann gilt man als Autor*in einer Arbeit? Was ist ein genuiner Beitrag? Was muss bei einer Publikation mit Blick auf die #GWP beachtet werden? 1/3

Progressive Voices Award 2025 - Brand New Bundestag Bereits das dritte Jahr in Folge lenken wir den Blick bewusst auf das Mutmachende in Politik und Gesellschaft und verleihen den Progressive Voices Award 2025.

Wissenschaft für Demokratie – Wir für Dich e.V. – ist für den Progressive Voices Award 2025 nominiert worden! 🎉. Stimmt ab, Ihr habt 5 Stimmen, auch in den anderen Kategorien für tolle Initiativen

Abstimmung: brandnewbundestag.de/progressive-...

Teilen ausdrücklich erwünscht! 💜

💪 Selbstwirksam aktiv gegen #RechteRaumnahme durch #Reichsbürger !

Unser Beratungsfall aus #Halsbrücke #Sachsen ist ein schönes Beispiel dafür, wie zivilgesellschaftliches Engagement gg #Rechtsextremismus in langfristiges, konstruktives Engagement für #Demokratie münden kann.

Cell-specific analysis of microglia following partial brain proton irradiation in mice In recent years, proton therapy has been established as a curative treatment for pediatric brain tumors and has demonstrated significant potential for adult brain tumors [1,2]. The advantage of proton...

After brain irradiation, microglia density increases with dose, more in the periventricular region. Correlation with contrast enhancementin MRI -- potential mechanism of brain necrosis. #RadOnc @hzdr.bsky.social @oncoalert.bsky.social

www.ctro.science/article/S240...

Zum ersten Mal hybrid Fortbildung für Patientenvertreter und Interessierte auf dem #DEGRO Kongress. Danke den ca 80 Teilnehmer:innen, davon 40 vor Ort. Und den Mitorganisatoren. @dkfz.bsky.social

Danke an die co-Kongresspräsidentinnen Esther Troost und Andrea Wittig und die Kongress- Koordinatorin Katja Storch #DEGRO

Der #DEGRO Kongress geht heute zuende. Sehr spannende Sitzung: was können wir eigentlich aus welchen Studien schlussfolgern?

Vienna outside of the conference Center 😊 #ESTRO25

Two of the talks in the best papers session came from Dresden. Congratulations Martina Palkowitsch, PhD student, and Annett Linge, clinician scientist. #ESTRO25 #radonc

I’m SO delighted to finally see first STAR-TREC data reported 🤩 #ESTRO25

Short course RT vs chemorad for organ preservation in early stage rectal cancer

61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad!
#radonc #rectalcancer

HYPO-RT-PC Phase III trial: Two-Week Radiotherapy Proven as Safe and Effective as Eight-Week Course for Prostate Cancer, After 10-Year Follow-Up - OncoDaily HYPO-RT-PC trial shows that ultra-hypofractionated radiotherapy is as effective and safe as 8-weektx for localized prostate cancer

oncodaily.com/societies/hy...

RFK Jr. Orders Search for New Measles Treatments Instead of Urging Vaccination Decades of research have turned up no miracle treatment for measles, but studies show the M.M.R. shot is 97 percent effective in preventing the disease.

Robert F. Kennedy Jr. will direct federal health agencies to explore potential new treatments for measles as the U.S. faces its largest outbreak in 25 years. Experts fear the decision could have grave consequences, as studies show the existing vaccine is 97% effective in preventing infection.

Congratulations Michael Baumann @dkfz.bsky.social to the Jens Overgaard Legacy Award #ESTRO25 #RadOnc

Try at Boston Scientific. Little queue, good coffee ☕️

This is currently the only plausible reason. We should not ignore that but find out if there are subgroups (what they tried and could not identify)

Birgitte Offersen showing the results of Skagen1 trial - hypofx vs conventional RT in high risk breast cancer patients with indication for lymphnode irradiation. Same side effects, same local control but worse survival. Due to lower RT dose? #ESTRO25 #RadOnk

At Sep 7th 1953 the first patient hast received radiotherapy with a linear accelerator.
Sept 7th, 2025 will be the world radiotherapy awareness day.
Safe and effektive treatment to cure cancer. Equal access worldwide still a problem.

Erstmalig aktive Patientenbeteiligung. Fortbildungsprogramm und aktive Beteiligung in ausgewählten Sitzungen. Selbsthilfegruppen sind vor Ort. Anmeldung notwendig (kostenfrei)
www.degro-kongress.org/rahmenprogra...

DEGRO 2025 – Radioonkologie [Teamwork] Maßgeschneidert. Patientenzentriert. Zukunftsorientiert. Selbstbestimmt im Team Der 31. Kongress der Deutschen Gesellschaft für Radioonkologie findet vom 19. bis 21. Juni 2025 in Dresden statt.

www.degro-kongress.org
DEGRO-Kongress, 19.-21.06.2025 in der Messe Dresden. Hochwertige Wissenschaft + schöne Stadt. Sehr viele haben sich schon angemeldet - Sie auch?
Patienten unten weiterlesen

Congratulations!

Great and much needed trial, looking forward the tumor outcome

A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study Chemotherapy (CT) is the standard of care for patients presenting with unresectable advanced gallbladder carcinoma (GBC) but their prognosis remains poor. The value of consolidation CT and radiation t...

RACE-GB, the first ever phase 3 randomized study showing overall survival improvement from chemotherapy combined with #radiation for gallbladder cancer.
Article: www.redjournal.org/article/S036...
Podcast: www.redjournal.org/audio-do/red...

The INSEMA trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results and Research Summary: nej.md/41o5L0Z

#MedSky #Oncology